Stocktoria
Translational Development Acquisition Corp. TDAC
Nasdaq · XNAS · stock · Blank Checks · IPO 2024-12-23
Chart by TradingView
2/9
Piotroski F — financial health
-1.21
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$944,538 | -$196,358 | -$485,550 |
| Net income | $6.4M | -$71,012 | -$485,550 |
| Operating cash flow | -$608,387 | -$851,446 | -$204 |
| Total assets | $181.7M | $175.0M | $2,021 |
| Total liabilities | $6.6M | $6.2M | $509,679 |
| Shareholders' equity | -$6.5M | -$5.6M | -$507,658 |
| Ratios | |||
| Return on assets | 3.5% | -0.0% | -24025.2% |
| Return on equity | -97.3% | 1.3% | 95.6% |
| Current ratio | 0.07 | 3.09 | 0.00 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.21 (distress)
- Working capital / assets -0.003
- Retained earnings / assets -0.036
- EBIT / assets -0.005
- Equity / liabilities -0.994
Sector peers
IX · MUFG · MFG · NMR · UNH · CI · all Finance, Insurance & Real Estate →
Source: SEC EDGAR filings · CIK 0001926599 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.